Abstract: A method for forming an implant hard mask on a substrate provides a multi-layer hardmask resistant to high processing temperatures and ion energies. In some embodiments, the method may comprise depositing a screen layer of oxide material with a thickness of approximately 20 nm to approximately 100 nm, depositing a first layer of the implant hard mask of amorphous carbon with a second thickness of approximately 100 nm to approximately 3000 nm; depositing a second layer of the implant hard mask of oxide with a third thickness of approximately 100 nm to approximately 3000 nm; depositing a photoresist layer on the second layer of the implant hard mask, and patterning the photoresist layer to expose portions of the second layer of the implant hard mask, etching the second layer of the implant hard mask and then the first layer of the implant hard mask using a hard mask etch process to expose portions of the screen layer.

Abstract: A pixel of a display device may pre-charge a light emitting element in non-emission periods immediately before emission periods by varying a voltage level of an initialization voltage. As a result, a luminance non-uniformity phenomenon that may occur as the result of a deterioration deviation of the light emitting element may be removed or reduced.

Abstract: Provided is a wastewater purification method, the method including: supplying a first mixed stream, in which an acid component and wastewater including water, a nitrile-based monomer, and ammonia are mixed, to a first column; recovering the nitrile-based monomer from an upper discharge stream from the first column; supplying a second mixed stream, in which a lower discharge stream from the first column and a base component are mixed, to a second column; and recovering the ammonia from an upper discharge stream from the second column and separating purified wastewater.

Abstract: A sealing structure may include a lid including a first lid face, a second lid face opposite to the first lid face, and a fragile area between the first lid face and the second lid face, a cover including a first cover face facing the second lid face and covering the fragile area and a second cover face opposite to the first cover face, wherein a first distance between the second lid face and the first cover face is substantially equal to or less than a second distance between the first cover face and the second cover face, and a connector configured to connect the lid and the cover.

Abstract: Disclosed is a stable liquid formulation, comprising an antibody or antigen-binding portion thereof, an acetate buffer, glycine, and a surfactant, wherein the stable liquid formulation does not comprise at least one of sugar, a sugar alcohol and a metal salt, and the stable liquid formulation is still stable even upon high antibody content, and is superior in osmolality and viscosity, and subcutaneous administration thereof is possible.

Abstract: An embodiment includes: a lens assembly including a fixed lens group and a first lens group that is movable in a first axis direction; an image sensor which detects light passing through the fixed lens group and the first lens group; an optical member which irradiates light to the fixed lens group and is tiltable with respect to a second axis or a third axis, which are perpendicular to the first axis; and a control unit storing correction values for correcting the tilt of an optical axis of the lens assembly.

Abstract: A stable liquid pharmaceutical preparation of an anti-influenza virus antibody and, more specifically, a stable liquid pharmaceutical preparation that comprises: (A) an anti-influenza virus antibody or a mixture of two or more different types of anti-influenza virus antibodies; (B) a surfactant; (C) a sugar or a sugar derivative; and (D) an amino acid. The stable liquid pharmaceutical preparation for an anti-influenza virus antibody disclosed herein has excellent storage stability at low temperature (5° C.), room temperature (25° C.), and high temperature (40° C.) and excellent long-term (12 months) storage stability, and may be administered intravenously, intramuscularly, transdermally, subcutaneously, intraperitoneally, topically, or in combinations thereof.

Abstract: The present invention provides a stable liquid pharmaceutical formulation containing: an antibody or its antigen-binding fragment; a surfactant; a sugar or its derivative; and a buffer. The stable liquid pharmaceutical formulation according to the present invention has low viscosity while containing a high content of the antibody, has excellent long-term storage stability based on excellent stability under accelerated conditions and severe conditions, and may be administered subcutaneously.

Abstract: The present invention provides a stable liquid pharmaceutical formulation containing: an antibody or its antigen-binding fragment; a surfactant; a sugar or its derivative; and a buffer. The stable liquid pharmaceutical formulation according to the present invention has low viscosity while containing a high content of the antibody, has excellent long-term storage stability based on excellent stability under accelerated conditions and severe conditions, and may be administered subcutaneously.

Abstract: A camera device calibration method according to one embodiment comprises the steps of: acquiring first data including location values of a first zoom lens and location values of a first focus lens, corresponding to the location values of the first zoom lens; setting at least two location points of the first zoom lens; acquiring at least two location values, which correspond to the location values of the first focus lens corresponding to at least two location points of the first zoom lens; acquiring second data corresponding to a value between at least two location values of the first zoom lens; and setting, in a camera including the first zoom lens and the first focus lens, at least two location values of the first zoom lens and the first focus lens when a difference value, which is acquired by comparing the first data with the second data, is within a preset threshold range.

Abstract: Disclosed is a stable liquid formulation, comprising an antibody or antigen-binding portion thereof, an acetate buffer, glycine, and a surfactant, wherein the stable liquid formulation does not comprise at least one of sugar, a sugar alcohol and a metal salt, and the stable liquid formulation is still stable even upon high antibody content, and is superior in osmolality and viscosity, and subcutaneous administration thereof is possible.

Abstract: Provided are a shaper unit and an image stabilization device. A shaper unit, according to one aspect of the present invention, comprises: a shaper body formed of a transparent material; first glass disposed on one side of the shaper body; a membrane disposed on one side of the first glass; a variable prism disposed on one side of the membrane; and a second glass disposed on one side of the variable prism.

Abstract: According to an embodiment of the present invention, an actuator control apparatus comprises: an actuator changing an optical path of a lens; and a controller controlling the actuator, wherein the actuator comprises a first driver and a second driver which are arranged on a first side of a lens support member, and a third driver and a fourth driver which are arranged on a second side of the lens support member. A first distance between the first driver and the second driver is different from a second distance between the first driver and the third driver, and the first driver and the fourth driver are located in a diagonal direction with respect to each other. The controller applies a first current to the second driver and the third driver and applies a second current to the first driver and the fourth driver. When the lens is moved in a diagonal direction, an absolute value of the first current is different from an absolute value of the second current.

Abstract: The present invention provides a stable liquid pharmaceutical formulation containing: an antibody or its antigen-binding fragment; a surfactant; a sugar or its derivative; and a buffer. The stable liquid pharmaceutical formulation according to the present invention has low viscosity while containing a high content of the antibody, has excellent long-term storage stability based on excellent stability under accelerated conditions and severe conditions, and may be administered subcutaneously.

Abstract: A camera actuator according to an embodiment includes a moving part including a lens; and a driving part for moving the moving part in the optical axis direction; wherein the driving part includes: a circuit board; a sensing part disposed on the circuit board and sensing a position of the moving part; and a driver IC disposed on the circuit board and connected to the sensing part; wherein the sensing part includes first and second sensing parts, and wherein a distance between the first sensing part and the driver IC corresponds to a distance between the second sensing part and the driver IC.

Abstract: An embodiment of the present invention discloses a camera actuator comprising: a housing; a mover disposed in the housing and including an optical member, and a drive disposed in the housing so as to drive the mover, wherein: the drive comprises a drive magnet, a drive coil placed opposite to the drive magnet, a sensor unit for sensing the position of the mover, and a substrate unit connected to the sensor unit, and a second sensor unit opposite to and connected in series to the first sensor unit.

Abstract: A pixel of a display device may pre-charge a light emitting element in non-emission periods immediately before emission periods by varying a voltage level of an initialization voltage. As a result, a luminance non-uniformity phenomenon that may occur as the result of a deterioration deviation of the light emitting element may be removed or reduced.

Abstract: The stable pharmaceutical formulation according to the present disclosure comprises (A) an antibody or antigen-binding fragment thereof that binds to an interleukin-6 receptor; (B) a surfactant; (C) stabilizers; and (D) a buffer. The stable pharmaceutical formulation according to the present disclosure has a low viscosity even when it contains an antibody, especially at a high concentration, and has excellent long-term storage stability based on excellent stability under accelerated and severe conditions, and may be administered intravenously or subcutaneously.

Abstract: A stable pharmaceutical formulation according to the present disclosure contains: a recombinant fusion protein; a surfactant; a sugar or a derivative thereof; a buffer; and an isotonic agent. The stable pharmaceutical formulation according to the present disclosure has low viscosity while containing the recombinant fusion protein, may maintain excellent stability under long-term storage conditions, accelerated conditions and stress conditions, and may be administered intraocularly.

Abstract: A stable liquid pharmaceutical formulation according to the present invention includes an antibody or antigen-binding fragment thereof, a surfactant, a sugar or a sugar derivative, a buffer, and a stabilizer. The stable liquid pharmaceutical formulation according to the present invention has low viscosity not only when antibody content is low but also when antibody content is high, and exhibits superior long-term storage stability based on superior stability observed under accelerated conditions and harsh conditions.